Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
65.46 USD | -0.12% | +0.40% | -19.20% |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
End-of-day quotes
Sector Other Pharmaceuticals
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
81.73B | ||||||
690B | ||||||
546B | ||||||
358B | ||||||
323B | ||||||
287B |